Tissue engineering

Tissue engineering is the construction of functional living tissue by combining cells, a supporting scaffold and biochemical or mechanical signals, either in a bioreactor before implantation or inside the body afterwards. The term was fixed by a 1993 Science article by Robert Langer and Joseph Vacanti that set out the field's programme and its founding triad.¹ Three decades later the discipline has delivered approved treatments for skin, cartilage, cornea and thymus, and none for a kidney, liver or heart. The distance between those two lists is the field's defining fact.

§The triad

The classical formulation has three components.

Cells provide the biological function. They may be autologous — taken from the patient, expanded in culture, and returned, which avoids rejection but takes weeks and cannot be stockpiled — or allogeneic, which allows an off-the-shelf product but usually requires immunosuppression or immune-privileged siting. Increasingly they are derived from Induced pluripotent stem cells, which decouples supply from donor tissue at the cost of differentiation and safety work.

Scaffold provides shape, mechanical support and a surface for attachment. Early scaffolds were synthetic polyesters already approved as resorbable sutures: polyglycolic acid, polylactic acid, their copolymers, and polycaprolactone. These degrade by hydrolysis on a tunable timescale, ideally matched to the rate at which cells lay down their own matrix. Natural scaffolds — collagen, fibrin, silk, and stripped donor tissue as described in Decellularized scaffolds — trade manufacturing control for better biological cues.

Signals are the growth factors, matrix stiffness, oxygen tension and mechanical loading that tell cells what to become. A scaffold seeded with chondrocytes and left static produces poor cartilage; the same construct under cyclic compression in a bioreactor produces better cartilage. Mechanical conditioning turned out to be as important as any molecule.

§Origins

1. 1975
   Keratinocyte culture
   Howard Green and James Rheinwald establish serial cultivation of human epidermal keratinocytes, making cultured skin grafts possible and giving the field its first clinical foothold.
2. 1988
   The term enters use
   A National Science Foundation workshop popularises 'tissue engineering' as a name for the emerging combination of biomaterials and cell biology.
3. 1993
   The programme stated
   Langer and Vacanti's Science article sets out cells-plus-scaffold-plus-signals as a general strategy for replacing lost tissue, and is taken as the field's founding document.
4. 1997
   The ear mouse
   Charles Vacanti's group grows human-ear-shaped cartilage on a polymer scaffold implanted under the skin of an athymic mouse. The image travels far beyond the science it represents.
5. 1997–2001
   First approvals
   Autologous chondrocyte implantation and engineered skin substitutes reach the market, followed within a few years by the commercial collapse of several of their manufacturers.
6. 2006
   Engineered bladders
   Anthony Atala's group reports autologous bladder constructs implanted in seven young patients with spina bifida, the first engineered organ-like structure followed for years in humans.

The ear mouse deserves separate mention because it shaped public expectation more than any result in the field. The construct was cartilage — avascular, mechanically simple, immunologically quiet — grown in an immunodeficient animal that could not reject it. It demonstrated that a polymer scaffold could hold a complex shape while cells filled it in. It demonstrated nothing about vascularized organs, and it was read as though it had.

§What reached the clinic

Engineered tissues in routine or approved use share a profile: thin, avascular or thinly vascularized, and small enough that diffusion suffices.

Cultured epidermal autografts have been used for massive burns since the 1980s. Bilayered skin substitutes combining allogeneic fibroblasts and keratinocytes on a collagen or polymer matrix are approved for chronic wounds; they act largely as living dressings that release growth factors rather than as permanent grafts. Autologous chondrocyte implantation, first approved in the United States in 1997 and superseded by a matrix-associated version in 2016, treats focal cartilage defects in the knee. Cultured limbal stem cell grafts for corneal burns received European approval in 2015. Allogeneic cultured thymus tissue for children born without a thymus was approved in the United States in 2021, and is one of the few products that reconstitutes an organ's function rather than patching a surface.

Atala's bladder work remains the most ambitious result with long human follow-up: autologous urothelial and muscle cells seeded on a biodegradable scaffold and implanted, with functional improvement sustained over years in a small cohort.² The attempt to commercialize it failed, as did several contemporaneous ventures. The commercial failures were not primarily scientific. Autologous products are closer to a service than a manufactured good, with a batch size of one, a cold chain, and a reimbursement code that often does not exist. This is the gap between laboratory validation and operational use that Technology readiness level describes, and it determines pricing and therefore the questions raised in Access and inequality.

Why the simple tissues worked

Every clinically successful engineered tissue is one where oxygen can diffuse from surrounding host tissue to every cell. That single physical constraint, not regulatory caution or funding, separates the products that exist from the ones that do not.

§Why organs did not follow

Four obstacles have proved durable.

Vascularization. A construct thicker than roughly a millimetre needs its own blood supply. Building a capillary bed remains unsolved, whether by printing it, as in Organ bioprinting, by reusing a donor organ's vascular tree, or by relying on host angiogenesis, which grows in at roughly a fraction of a millimetre per day — too slow for a thick construct.

Cell number and phenotype. A liver contains on the order of a hundred billion cells, and primary hepatocytes dedifferentiate within days outside the body. Producing enough cells of the right type, in the right state, remains a manufacturing problem as much as a biological one.

Maturation. Stem-cell-derived tissue is fetal-like. Cardiomyocytes contract weakly, neurons are electrically immature, and no reliable protocol drives them to adult phenotype on a useful timescale. The same ceiling limits Organoids. Cells taken from an elderly recipient bring a second problem, the functional decline catalogued under Stem cell exhaustion, which is part of why several groups have proposed combining autologous cell manufacture with Epigenetic reprogramming to restore proliferative capacity before use.

Integration. An implanted construct must connect to host vasculature, innervation, and in some cases a duct or lumen, and must survive the host's foreign-body response. Work by Jennifer Elisseeff's group showed, in a mouse muscle-injury model, that biomaterial scaffolds elicit a type 2 immune response involving T cells that determines whether the outcome is regeneration or fibrosis, reframing the immune system as an active participant in the repair rather than an obstacle to be suppressed. The same dependence has not been demonstrated in humans.³

§Current directions

The field's centre of gravity has shifted in three ways. First, away from the pre-fabricated construct and toward in vivo tissue engineering, where an acellular material recruits the patient's own cells and the body serves as the bioreactor; most commercially successful regenerative products now work this way. Second, toward immunomodulatory design, in which the scaffold's job is to steer macrophage and T-cell behaviour rather than merely to provide shape. Third, toward biofabrication methods that give spatial control, including printing, moulding of tissue building blocks, and assembly of organoid units into larger structures.

Two adjacent products show how the boundary of the field has moved. Engineered cardiac patches are being developed as an adjunct to, not a replacement for, the mechanical circulatory support described in Artificial heart. Cultured red cells, discussed in Artificial blood, are an engineered tissue in everything but name, and face a manufacturing problem of scale rather than architecture.

Engineered tissue has also found a market that does not require implantation at all. Liver, cardiac and tumour tissue built on chips or in multiwell formats is used for toxicity screening, and demand grew as regulators moved away from mandatory animal testing for some drug classes — the same shift that names the computational models described in Human digital twins among the acceptable alternatives.

§Outlook

Tissue engineering is a mature field with a modest clinical footprint and an unmet founding promise. Its practitioners generally no longer forecast a printed kidney; they forecast incremental gains in islet constructs, vascular grafts, nerve conduits, corneal tissue and cardiac patches, each of which is a real clinical need served by a few cubic centimetres of tissue. Whether the discipline ever produces one of the Lab-grown organs it was founded to deliver depends on the vascular problem, and the strongest current argument is that any answer would come from combining a biologically constructed capillary bed with an engineered large-vessel framework rather than from fabricating either alone. The alternative is to stop building and start inducing, which is why the biology of animals that rebuild structures on their own, covered in Limb regeneration, has drawn renewed attention from engineers. Meanwhile the Organ shortage is being addressed by Xenotransplantation, machine perfusion and donation policy, all of which were considered less likely than engineered organs when the field was named. The same ordering holds in reproductive medicine, where Uterus transplantation has produced live births while recellularized uterine scaffolds remain in animal work.

§See also

• Organ bioprinting
• Decellularized scaffolds
• Organoids
• Lab-grown organs
• Induced pluripotent stem cells
• Limb regeneration
• Organ shortage
• Stem cell exhaustion

§References